Jennifer Kayden Lee - Feb 11, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of North America
Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Chien
Stock symbol
RYTM
Transactions as of
Feb 11, 2023
Transactions value $
-$17,062
Form type
4
Date filed
2/14/2023, 07:59 PM
Previous filing
Feb 14, 2023
Next filing
Aug 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +2.03K +57.31% 5.58K Feb 11, 2023 Direct F1
transaction RYTM Common Stock Sale -$17.1K -635 -11.39% $26.87 4.94K Feb 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -2.03K -33.33% $0.00 4.06K Feb 11, 2023 Common Stock 2.03K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.